TBVI is continuously working on the development of new vaccine candidates.
The current TB vaccine pipeline (last update October 2020), is as follows:
TBVI provides technical support for product and clinical development to TB vaccine researchers and developers.
TBVI has initiated and coordinated the realisation of a joint publication regarding preferred product characteristics (PPC) for therapeutic vaccines to improve tuberculosis treatment outcomes. This PPC is a result of a consensus generating consultation process from the WHO, TBVI and IAVI with input from experts within the TB field and beyond. To read the full publication, please follow the link: “Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations”.
TB Vaccine development pathway
The TB vaccine pipeline requires a global and comprehensive coordination of efforts with defined stages of development and criteria for progression of individual vaccine candidates. To address this, the TB Vaccine Development Pathway is a newly established tool that provides a structured development path and gating criteria for TB vaccine candidates. It also describes the different functions and capabilities required to advance a candidate TB vaccine to its next stage of development. For more information about the Pathway, please visit www.TBVacPathway.org and / or read the article published in Tuberculosis The TB vaccine development pathway – An innovative approach to accelerating global TB vaccine development.
For more information, please contact Daniëlle Roordink.